Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 47

1.

Genomic Characterization of Primary Invasive Lobular Breast Cancer.

Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M, Fumagalli D, Brown D, Rothé F, Vincent D, Kheddoumi N, Rouas G, Majjaj S, Brohée S, Van Loo P, Maisonneuve P, Salgado R, Van Brussel T, Lambrechts D, Bose R, Metzger O, Galant C, Bertucci F, Piccart-Gebhart M, Viale G, Biganzoli E, Campbell PJ, Sotiriou C.

J Clin Oncol. 2016 Feb 29. pii: JCO640334. [Epub ahead of print]

PMID:
26926684
2.

Crowdfunding for Personalized Medicine Research.

Fumagalli DC, Gouw AM.

Yale J Biol Med. 2015 Nov 24;88(4):413-4. eCollection 2015 Dec. Review.

3.

Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome.

Fumagalli D, Gacquer D, Rothé F, Lefort A, Libert F, Brown D, Kheddoumi N, Shlien A, Konopka T, Salgado R, Larsimont D, Polyak K, Willard-Gallo K, Desmedt C, Piccart M, Abramowicz M, Campbell PJ, Sotiriou C, Detours V.

Cell Rep. 2015 Oct 13;13(2):277-89. doi: 10.1016/j.celrep.2015.09.032. Epub 2015 Oct 1.

4.

Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.

Sonnenblick A, Brohée S, Fumagalli D, Rothé F, Vincent D, Ignatiadis M, Desmedt C, Salgado R, Sirtaine N, Loi S, Neven P, Loibl S, Denkert C, Joensuu H, Piccart M, Sotiriou C.

Oncotarget. 2015 Oct 6;6(30):30306-16. doi: 10.18632/oncotarget.5080.

5.

Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer.

Sonnenblick A, Brohée S, Fumagalli D, Vincent D, Venet D, Ignatiadis M, Salgado R, Van den Eynden G, Rothé F, Desmedt C, Neven P, Loibl S, Denkert C, Joensuu H, Loi S, Sirtaine N, Kellokumpu-Lehtinen PL, Piccart M, Sotiriou C.

BMC Med. 2015 Aug 3;13:177. doi: 10.1186/s12916-015-0416-2.

6.

No significant viral transcription detected in whole breast cancer transcriptomes.

Fimereli D, Gacquer D, Fumagalli D, Salgado R, Rothé F, Larsimont D, Sotiriou C, Detours V.

BMC Cancer. 2015 Mar 18;15:147. doi: 10.1186/s12885-015-1176-2.

7.

Uncovering the genomic heterogeneity of multifocal breast cancer.

Desmedt C, Fumagalli D, Pietri E, Zoppoli G, Brown D, Nik-Zainal S, Gundem G, Rothé F, Majjaj S, Garuti A, Carminati E, Loi S, Van Brussel T, Boeckx B, Maetens M, Mudie L, Vincent D, Kheddoumi N, Serra L, Massa I, Ballestrero A, Amadori D, Salgado R, de Wind A, Lambrechts D, Piccart M, Larsimont D, Campbell PJ, Sotiriou C.

J Pathol. 2015 Aug;236(4):457-66. doi: 10.1002/path.4540. Epub 2015 May 7.

8.

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.

Majewski IJ, Nuciforo P, Mittempergher L, Bosma AJ, Eidtmann H, Holmes E, Sotiriou C, Fumagalli D, Jimenez J, Aura C, Prudkin L, Díaz-Delgado MC, de la Peña L, Loi S, Ellis C, Schultz N, de Azambuja E, Harbeck N, Piccart-Gebhart M, Bernards R, Baselga J.

J Clin Oncol. 2015 Apr 20;33(12):1334-9. doi: 10.1200/JCO.2014.55.2158. Epub 2015 Jan 5.

9.

Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology.

Fumagalli D, Blanchet-Cohen A, Brown D, Desmedt C, Gacquer D, Michiels S, Rothé F, Majjaj S, Salgado R, Larsimont D, Ignatiadis M, Maetens M, Piccart M, Detours V, Sotiriou C, Haibe-Kains B.

BMC Genomics. 2014 Nov 21;15:1008. doi: 10.1186/1471-2164-15-1008.

10.

New strategies in breast cancer: the significance of molecular subtypes in systemic adjuvant treatment for small T1a,bN0M0 tumors.

Sonnenblick A, Fumagalli D, Azim HA Jr, Sotiriou C, Piccart M.

Clin Cancer Res. 2014 Dec 15;20(24):6242-6. doi: 10.1158/1078-0432.CCR-14-1086. Epub 2014 Oct 21. Review.

11.

Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data.

Lönnstedt IM, Caramia F, Li J, Fumagalli D, Salgado R, Rowan A, Salm M, Kanu N, Savas P, Horswell S, Gade S, Loibl S, Neven P, Sotiriou C, Swanton C, Loi S, Speed TP.

Genome Biol. 2014 Oct 1;15(9):470. doi: 10.1186/s13059-014-0470-7.

12.

The AURORA initiative for metastatic breast cancer.

Zardavas D, Maetens M, Irrthum A, Goulioti T, Engelen K, Fumagalli D, Salgado R, Aftimos P, Saini KS, Sotiriou C, Campbell P, Dinh P, von Minckwitz G, Gelber RD, Dowsett M, Di Leo A, Cameron D, Baselga J, Gnant M, Goldhirsch A, Norton L, Piccart M.

Br J Cancer. 2014 Nov 11;111(10):1881-7. doi: 10.1038/bjc.2014.341. Epub 2014 Sep 16. Review.

13.

Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.

Rothé F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, Fumagalli D, Michiels S, Drisis S, Moerman C, Detiffe JP, Larsimont D, Awada A, Piccart M, Sotiriou C, Ignatiadis M.

Ann Oncol. 2014 Oct;25(10):1959-65. doi: 10.1093/annonc/mdu288. Epub 2014 Jul 25.

14.

Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?

Sonnenblick A, Fumagalli D, Sotiriou C, Piccart M.

Cancer Treat Rev. 2014 Oct;40(9):1089-95. doi: 10.1016/j.ctrv.2014.07.005. Epub 2014 Aug 12. Review.

PMID:
25151406
15.

Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.

Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, Viale G, Sotiriou C, Piccart M.

J Clin Oncol. 2014 Sep 1;32(25):2794-803. doi: 10.1200/JCO.2013.54.1870. Epub 2014 Jul 21. Review.

PMID:
25049332
16.

Modelling soil borne fungal pathogens of arable crops under climate change.

Manici LM, Bregaglio S, Fumagalli D, Donatelli M.

Int J Biometeorol. 2014 Dec;58(10):2071-83. doi: 10.1007/s00484-014-0808-6. Epub 2014 Mar 11.

PMID:
24615638
17.

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart MJ, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C.

Ann Oncol. 2014 Aug;25(8):1544-50. doi: 10.1093/annonc/mdu112. Epub 2014 Mar 7.

18.

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

Pogue-Geile KL, Kim C, Jeong JH, Tanaka N, Bandos H, Gavin PG, Fumagalli D, Goldstein LC, Sneige N, Burandt E, Taniyama Y, Bohn OL, Lee A, Kim SI, Reilly ML, Remillard MY, Blackmon NL, Kim SR, Horne ZD, Rastogi P, Fehrenbacher L, Romond EH, Swain SM, Mamounas EP, Wickerham DL, Geyer CE Jr, Costantino JP, Wolmark N, Paik S.

J Natl Cancer Inst. 2013 Dec 4;105(23):1782-8. doi: 10.1093/jnci/djt321. Epub 2013 Nov 21.

19.

Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.

Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Piccart MJ, Joensuu H, Sotiriou C.

J Natl Cancer Inst. 2013 Jul 3;105(13):960-7. doi: 10.1093/jnci/djt121. Epub 2013 Jun 5.

20.

Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysis.

Azim HA Jr, Singhal S, Ignatiadis M, Desmedt C, Fumagalli D, Veys I, Larsimont D, Piccart M, Michiels S, Sotiriou C.

PLoS One. 2013 Apr 26;8(4):e62451. doi: 10.1371/journal.pone.0062451. Print 2013. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/3d5a5933-791f-4191-98f5-f559a872e404.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk